BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 25240281)

  • 1. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
    Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
    Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
    Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
    Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
    Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
    Zhang X; Murray B; Mo G; Shern JF
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
    Prieto-Granada CN; Wiesner T; Messina JL; Jungbluth AA; Chi P; Antonescu CR
    Am J Surg Pathol; 2016 Apr; 40(4):479-89. PubMed ID: 26645727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
    Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
    Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
    Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
    Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of PRC2 function promotes MPNST pathogenesis.
    Cancer Discov; 2014 Nov; 4(11):OF14. PubMed ID: 25367955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
    Kochat V; Raman AT; Landers SM; Tang M; Schulz J; Terranova C; Landry JP; Bhalla AD; Beird HC; Wu CC; Jiang Y; Mao X; Lazcano R; Gite S; Ingram DR; Yi M; Zhang J; Keung EZ; Scally CP; Roland CL; Hunt KK; Feig BW; Futreal PA; Hwu P; Wang WL; Lazar AJ; Slopis JM; Wilson-Robles H; Wiener DJ; McCutcheon IE; Wustefeld-Janssens B; Rai K; Torres KE
    Acta Neuropathol; 2021 Sep; 142(3):565-590. PubMed ID: 34283254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
    Lyskjaer I; Lindsay D; Tirabosco R; Steele CD; Lombard P; Strobl AC; Rocha AM; Davies C; Ye H; Bekers E; Ingruber J; Lechner M; Amary F; Pillay N; Flanagan AM
    J Pathol; 2020 Oct; 252(2):151-164. PubMed ID: 32666581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
    Owosho AA; Estilo CL; Huryn JM; Chi P; Antonescu CR
    Head Neck Pathol; 2018 Jun; 12(2):151-159. PubMed ID: 28762137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.
    Le Guellec S; Macagno N; Velasco V; Lamant L; Lae M; Filleron T; Malissen N; Cassagnau E; Terrier P; Chevreau C; Ranchere-Vince D; Coindre JM
    Mod Pathol; 2017 Dec; 30(12):1677-1687. PubMed ID: 28752843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens.
    Mito JK; Qian X; Doyle LA; Hornick JL; Jo VY
    Am J Clin Pathol; 2017 Aug; 148(2):179-189. PubMed ID: 28898989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.
    Agaram NP; Wexler LH; Chi P; Antonescu CR
    Genes Chromosomes Cancer; 2023 Mar; 62(3):131-138. PubMed ID: 36414547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
    Korfhage J; Lombard DB
    Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.
    Schaefer IM; Fletcher CD; Hornick JL
    Mod Pathol; 2016 Jan; 29(1):4-13. PubMed ID: 26585554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PRC2 alterations in NF1-associated malignant peripheral nerve sheath tumors: schwann cells with no complex].
    Luscan A; Vidaud D; Ortonne N; Wolkenstein P; Vidaud M; Pasmant E
    Med Sci (Paris); 2014; 30(8-9):733-5. PubMed ID: 25174745
    [No Abstract]   [Full Text] [Related]  

  • 20. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.